Rocket Lab Corp (RKLB) is having quite the week. On Friday afternoon, shares jumped 7.28% to $97.37 after Morgan Stanley delivered a substantial upgrade, moving the stock from Equal-Weight to Overweight and nearly doubling its price target from $67 to $105. That's a bold call suggesting roughly 50% upside from current levels.

The timing is particularly interesting because just Thursday, Rocket Lab traded lower following a downgrade from Keybanc. So we've got dueling narratives here: one firm saying the party's over, another saying it's just getting started.

The Case for Caution: Keybanc Taps the Brakes

Keybanc analyst Michael Leshock downgraded Rocket Lab from Overweight to Sector Weight on Thursday, essentially arguing that all the good news is already baked into the stock price. The firm isn't saying Rocket Lab is a bad company—quite the opposite, actually. They call it one of the highest-quality names in the space sector and point to impressive recent wins like an $816 million contract award and a shiny new launch pad.

The downgrade reflects more of a valuation concern than a business concern. Keybanc notes broader tailwinds for the space sector, including buzz around SpaceX's reported IPO plans and significant appointments within NASA. But in their view, the near-term risk-reward just isn't compelling enough to justify an aggressive stance. They do suggest that better visibility into upcoming launches could shift the picture more positive down the road.

The Technical Picture: Strong but Stretched

From a technical standpoint, Rocket Lab is showing some seriously bullish momentum—maybe too much of a good thing. The stock is trading 18.8% above its 20-day simple moving average and a whopping 57.5% above its 100-day SMA. Those are the kinds of numbers that make momentum traders smile and value investors nervous.

The 12-month performance tells the story: shares have rocketed 291.92% higher and are currently hovering much closer to their 52-week highs than lows. Impressive? Absolutely. Sustainable without a breather? That's the question.

The RSI reading of 71.99 puts the stock in overbought territory, which often signals that a pullback could be coming if momentum starts to fade. Meanwhile, the MACD remains above its signal line, reinforcing the bullish case. It's that classic tug-of-war between "this trend is strong" and "this trend might be overextended."

Traders watching the charts are likely eyeing two key levels: resistance at $100.00 and support at $90.00. Breaking through that century mark would be psychologically significant, while a dip back to $90 would test whether buyers are still committed.

What's Coming: Earnings on the Horizon

Investors won't have to wait long for the next major catalyst. Rocket Lab is scheduled to report earnings on February 26, and expectations are pointing toward continued growth.

Analysts are forecasting a loss of 9 cents per share, which would actually be an improvement from the 10-cent loss in the same quarter last year. More importantly, revenue is expected to jump to $178.29 million, up from $132.39 million year-over-year. That's roughly 35% revenue growth, which helps explain why momentum has been so strong despite the company still operating at a loss.

The Analyst Landscape

The consensus rating on Rocket Lab is Buy, though the average price target of $56.15 looks quaintly outdated given that the stock is trading nearly 75% above that level. Recent analyst activity shows a mixed but generally constructive picture:

• Morgan Stanley: Upgraded to Overweight with a $105.00 target (January 16)
• Keybanc: Downgraded to Sector Weight (January 15)
• Needham: Maintained Buy with a raised target of $90.00 (December 23, 2025)

Momentum Metrics Tell a Strong Story

Looking at the momentum scorecard, Rocket Lab scores an impressive 97.92 out of 100, indicating the stock is significantly outperforming the broader market. That kind of score suggests the upward trend has real legs, at least for now. Traders focused on momentum strategies are likely viewing this as a favorable setup, though the overbought technicals suggest timing matters.

The ETF Angle: Heavy Concentration Creates Volatility

Here's something interesting that doesn't always get enough attention: Rocket Lab carries meaningful weight in several aerospace and defense ETFs, which can amplify price movements.

• SPDR S&P Aerospace & Defense ETF (XAR): 5.66% weight
• First Trust Indxx Aerospace & Defense ETF (MISL): 4.81% weight
• ARK Space & Defense Innovation ETF (ARKX): 7.62% weight

When you're carrying nearly 8% of a fund's portfolio, you create a mechanical relationship between fund flows and your stock price. Big inflows into these ETFs mean automatic buying of Rocket Lab shares, and vice versa. It's worth keeping an eye on, especially during volatile periods.

The Bottom Line

Rocket Lab finds itself at an interesting crossroads. The business fundamentals look solid—growing revenue, major contracts, expanding infrastructure. The momentum is undeniably strong with nearly 300% gains over the past year. But the valuation debate is real, with smart analysts coming to different conclusions about whether there's more room to run.

Morgan Stanley's $105 target suggests they see another leg up. Keybanc's downgrade suggests the easy money has been made. The truth, as usual, probably lies somewhere in between. What's clear is that February 26 earnings will be closely watched, and whether the stock can punch through $100 or falls back to test $90 support will tell us a lot about investor conviction at these levels.